Can Fite Biopharma Ltd ADR Total Liabilities
Can Fite Biopharma Ltd ADR total liabilities. Based on the latest financial reports, Can Fite Biopharma Ltd ADR (CANF) has total liabilities worth $3.92 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Can Fite Biopharma Ltd ADR (CANF) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Can Fite Biopharma Ltd ADR (2011–2025)
Total liabilities of Can Fite Biopharma Ltd ADR from 2011 to 2025. This chart illustrates how Can Fite Biopharma Ltd ADR's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Can Fite Biopharma Ltd ADR to see how much of total assets are deployed in long-term investments.
Can Fite Biopharma Ltd ADR Competitors by Total Liabilities
The table below lists competitors of Can Fite Biopharma Ltd ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Pinewood Technologies Group PLC
LSE:PINE
|
UK | GBX21.10 Million |
|
Moving iMage Technologies Inc
NYSE MKT:MITQ
|
USA | $4.46 Million |
|
Nauticus Robotics Inc.
NASDAQ:KITT
|
USA | $30.75 Million |
|
Noble Financials SA
WAR:IBS
|
Poland | zł70.99 Million |
|
Pembangunan Graha Lestari Tbk
JK:PGLI
|
Indonesia | Rp21.09 Billion |
|
Amaze Holdings Inc
NYSE MKT:AMZE
|
USA | $24.44 Million |
|
Great Divide Mining Ltd
AU:GDM
|
Australia | AU$424.04K |
|
Snipp Interactive Inc
V:SPN
|
Canada | CA$13.42 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Can Fite Biopharma Ltd ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Can Fite Biopharma Ltd ADR.
Liquidity & Leverage Metrics
Can Fite Biopharma Ltd ADR Total Liabilities Ratios Explained
Can Fite Biopharma Ltd ADR total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.46 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.70 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Can Fite Biopharma Ltd ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Can Fite Biopharma Ltd ADR (2011–2025)
The table below shows the annual total liabilities of Can Fite Biopharma Ltd ADR from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.92 Million | +6.46% |
| 2024-12-31 | $3.68 Million | -1.66% |
| 2023-12-31 | $3.75 Million | -22.14% |
| 2022-12-31 | $4.81 Million | -18.05% |
| 2021-12-31 | $5.87 Million | +70.22% |
| 2020-12-31 | $3.45 Million | -39.83% |
| 2019-12-31 | $5.73 Million | +16.10% |
| 2018-12-31 | $4.94 Million | +3.32% |
| 2017-12-31 | $4.78 Million | -24.07% |
| 2016-12-31 | $6.29 Million | -12.06% |
| 2015-12-31 | $7.16 Million | +114.89% |
| 2014-12-31 | $3.33 Million | +52.99% |
| 2013-12-31 | $2.18 Million | -7.11% |
| 2012-12-31 | $2.34 Million | +45.41% |
| 2011-12-31 | $1.61 Million | -- |
About Can Fite Biopharma Ltd ADR
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase … Read more